Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study

Circulation

Volumn 108, Issue 15, 2003, Pages 1831-1838

  Pitt, Bertram ^a,i   Reichek, Nathaniel ^b   Willenbrock, Roland ^c   Zannad, Faiez ^d   Phillips, Robert A ^e,f   Roniker, Barbara ^g   Kleiman, Jay ^g   Krause, Scott ^g   Burns, Daniel ^g   Williams, Gordon H ^h  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Franz Volhard Klinik   (Germany)

^d Ctr Hospitalier Univ de Nancy   (France)

^e LENOX HILL HOSPITAL   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PFIZER INC   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Blood pressure; Hypertension; Hypertrophy; Ventricles

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; BRONCHODILATING AGENT; CYTOTOXIC AGENT; ENALAPRIL; EPLERENONE; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; IMMUNOSUPPRESSIVE AGENT; NITRATE; RENIN; SILDENAFIL; THEOPHYLLINE;

ACCIDENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CAPSULE; DRUG EFFECT; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; INJURY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 0142085752     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000091405.00772.6E     Document Type: Article

References (29)

1. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
2. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-2044.
3. Frohlich ED. Potential mechanisms explaining the risk of left ventricular hypertrophy. Am J Cardiol. 1987;59:91A-97A.
4. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
5. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
7. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
8. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads: 1949. Ann Noninvasive Electrocardiol. 2001;6:343-368.
9. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
10. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension. 2000;35:6-12.
11. Diercks GF, Stroes ES, van Boven AJ, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis. 2002;163:121-126.
12. Olsen MH, Wachtell K, Borch-Johnsen K, et al. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hum Hypertens. 2002;16:591-595.
13. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
14. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
15. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
16. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002;8:132-140.
17. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30:475-483.
18. 2+ in vascular smooth muscle cells. Circ Res. 1995;76:973-979.
19. Houchi H, Okuno M, Kitamura K, et al. Stimulatory effect of angiotensin II on calcium efflux from cultured bovine adrenal chromaffin cells. Life Sci. 1995;56:PL109-PL114.
20. Griendling KK, Rittenhouse SE, Brock TA, et al. Sustained diacyl-glycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem. 1986;261:5901-5906.
21. Clunn GF, Schachter M, Hughes AD. Contrasting mechanisms of intracellular calcium ([Ca2+]i) elevation by angiotensin II (AII) and platelet derived growth factor-BB (PDGF-BB) in human vascular smooth muscle cells (VSMCs). Biochem Soc Trans. 1995;23:170S.
22. Brock TA, Alexander RW, Ekstein LS, et al. Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells. Hypertension. 1985;7:1105-1109.
23. Robert V, Heymes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999;33:981-986.
24. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med. 1993;122:404-411.
25. Sun Y, Ratajska A, Zhou G, et al. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403.
26. Liu YJ, Nakagawa Y, Toya K, et al. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int. 2000;57:2064-2071.
27. Cal TQ, Wong B, Mundt SS, et al. Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol. 2001;77:117-122.
28. Mancia G, Carugo S, Grassi G. Primary prevention of cardiovascular disease. Cardiology. 1997;88(suppl 3):32-37.
29. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.